■由于其普遍性,复发,以及耐药性的出现,念珠菌阴道炎显著影响女性的健康。虽然肉桂精油(CEO)具有抗真菌活性,其疏水特性限制了其临床应用。
■为了克服这一挑战,采用纳米乳化技术制备肉桂精油纳米乳液(CEO@NE),研究了其对念珠菌阴道炎的体内外治疗效果和作用机制。
■CEO@NE,由4%的CEO组成,78%蒸馏水,用超声波纳米乳化法制备了18%的吐温80。物理性质,抗念珠菌活性,细胞毒性,探讨了CEO@NE的免疫调节潜力和储存稳定性。随后,在小鼠中研究了阴道内CEO@NE治疗对念珠菌性阴道炎的影响.为了理解CEO@NE的可能机制,进行分析以确定白色念珠菌中细胞内活性氧(ROS)的产生。
■CEO@NE,与液滴尺寸小于100纳米和强大的储存稳定性长达8周,表现出与首席执行官相当的抗念珠菌活性。浓度低于400μg/mL的CEO@NE对鼠脾细胞没有细胞毒性和免疫调节作用。CEO@NE的阴道内治疗(400μg/mL,20μL/天/小鼠,连续5天)抑制念珠菌定植,改善的组织病理学变化,并抑制了白色念珠菌阴道内攻击的小鼠的炎性细胞因子产生。值得注意的是,这种治疗保留了对阴道健康至关重要的阴道乳酸菌(LAB)的密度。与CEO@NE共培养白色念珠菌揭示了细胞内ROS产生的浓度依赖性增加和随后的细胞死亡。此外,将LPS刺激的小鼠脾细胞与CEO@NE共培养可减少细胞因子的产生。
■这一发现提供了对CEO@NE治疗念珠菌阴道炎的可想而知的抗真菌和抗炎机制的见解。CEO@NE提供了一个有希望的途径来解决当前治疗的局限性,为念珠菌阴道炎的治疗提供了新的策略。
UNASSIGNED: Due to its prevalence, recurrence, and the emergence of drug-resistance, Candida vaginitis significantly impacts the well-being of women. Although cinnamon essential oil (CEO) possesses antifungal activity, its hydrophobic properties limit its clinical application.
UNASSIGNED: To overcome this challenge, a nanoemulsification technology was employed to prepare cinnamon essential oil-nanoemulsion (CEO@NE), and its therapeutic efficacy and action mechanism for Candida vaginitis was investigated in vivo and in vitro.
UNASSIGNED: CEO@NE, composed of 4% CEO, 78% distilled water, and 18% Tween 80, was prepared by ultrasonic nanoemulsification. The physical properties, anti-Candida activity, cytotoxicity, immunomodulatory potential and storage stability of CEO@NE were explored. Subsequently, the effect of intravaginal CEO@NE treatment on Candida vaginitis was investigated in mice. To comprehend the possible mechanism of CEO@NE, an analysis was conducted to ascertain the production of intracellular reactive oxygen species (ROS) in C. albicans.
UNASSIGNED: CEO@NE, with the droplet size less than 100 nm and robust storage stability for up to 8 weeks, exhibited comparable anti-Candida activity with CEO. CEO@NE at the concentration lower than 400 μg/mL had no cytotoxic and immunomodulatory effects on murine splenocytes. Intravaginal treatment of CEO@NE (400 μg/mL, 20 μL/day/mouse for 5 consecutive days) curbed Candida colonization, ameliorated histopathological changes, and suppressed inflammatory cytokine production in mice intravaginally challenged with C. albicans. Notably, this treatment preserved the density of vaginal lactic acid bacteria (LAB) crucial for vaginal health. Co-culturing C. albicans with CEO@NE revealed concentration-dependent augmentation of intracellular ROS generation and ensuing cell death. In addition, co-culturing LPS-stimulated murine splenocytes with CEO@NE yielded a decrease in the generation of cytokines.
UNASSIGNED: This discovery provides insight into the conceivable antifungal and anti-inflammatory mechanisms of CEO@NE to tackle Candida vaginitis. CEO@NE offers a promising avenue to address the limitations of current treatments, providing novel strategy for treating Candida vaginitis.